期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

二肽基肽酶Ⅳ抑制剂西格列汀上市七年循证证据回顾 被引量：8

原文传递
导出
摘要 随着中国城市化、老龄化的进展与人民生活水平的提高，中国糖尿病治疗领域面临严峻挑战。西格列汀作为首个上市的二肽基肽酶IV（DPP-4）抑制剂，可通过增加活性肠促胰素水平而改善2型糖尿病患者的血糖控制。上市七年积累的大量循证医学证据表明，西格列汀降糖疗效与现有降糖药物相似，同时低血糖风险低，不增加体重，有潜在的心血管及微血管临床获益，满足2型糖尿病患者临床需要。
作者 邹大进
机构地区 [
出处 《中华糖尿病杂志》 CAS CSCD 2014年第1期61-64,共4页 CHINESE JOURNAL OF DIABETES MELLITUS
关键词 二肽基肽酶Ⅳ抑制剂 循证证据 上市 2型糖尿病 循证医学证据 降糖药物 血糖控制 生活水
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献35

  • 1Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) [ J]. Diabetes Care, 2012,35 : 1364-1379.
  • 2Garber AJ, Abrahamson M J, Barzilay Jl, et al. American Association of Clinical Endocrinologists. AACE comprehensive diabetes management algorithm 2013 [ J. Endocr Pract, 2013, 19:327-336.
  • 3Mohan V, Yang W, Son HY, et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea[ J]. Diabetes Res Clin Praet,2009,83: 106-116.
  • 4Aschner P, Kipnes MS, Lunceford JK, et al. Sitagliptin Stmly 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes [ J]. Diabetes Care,2006,29:2632-2637.
  • 5Rosenstock J, Brazg R, Andryuk PJ, et al. Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, muhicenter, randomized, double- blind, placebo-controlled, parallel-group study [ J]. Clin Ther, 2006,28 : 1556-1568.
  • 6Yang W, Guan Y, Shentu Y, et al. The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes [ J]. J Diabetes,2012,4 : 227 -237.
  • 7Raz I, Chen Y, Wu M, et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes [ J ]. Curr Med Res Opin, 2008,24:537-550.
  • 8Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin [ J ]. Diabetes Obes Metab, 2007,9 : 733-745.
  • 9Dobs AS, Goldstein BJ, Aschner P, et al. Efficacy and safety of sitagliptin added to ongoing mefformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes[ J]. J Diabetes, 2013,5:68- 79.
  • 10Vilsbll T, Rosenstoek J, Yki-Jiirvinen H, et al. Efficacy and safety of sitagliptinwhen added to insulin therapy in patients with type 2 diabetes[ J]. Diabetes Obes Metab, 2010,12 : 167-177.

共引文献5

同被引文献96

引证文献8

二级引证文献54

中华糖尿病杂志
2014年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部